ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

April 17, 2009

Buenos Aires Academy Denies Argentina Prosecutes Scientist

July 28, 1978

Cancer Groups Oppose Plan To Cut Drug Reimbursement.

July 28, 2000

NCI Launches NCORP with 53 Grants Totaling $465 Million

August 8, 2014

Center Directors To Rewrite 5-Year Plan With Little Staff Help

March 9, 1990

DCPC To Merge Two Programs, Reorganizes Chemoprevention

November 4, 1994